IBS-C Drugs-South America Market Status and Trend Report 2013-2023
Report Summary
IBS-C Drugs-South America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole South America and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023
Main market players of IBS-C Drugs in South America, with company and product introduction, position in the IBS-C Drugs market
Market status and development trend of IBS-C Drugs by types and applications
Cost and profit status of IBS-C Drugs, and marketing status
Market growth drivers and challenges
The report segments the South America IBS-C Drugs market as:
South America IBS-C Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Brazil
Argentina
Venezuela
Colombia
Others
South America IBS-C Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
South America IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South America IBS-C Drugs Market: Players Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
IBS-C Drugs-South America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole South America and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023
Main market players of IBS-C Drugs in South America, with company and product introduction, position in the IBS-C Drugs market
Market status and development trend of IBS-C Drugs by types and applications
Cost and profit status of IBS-C Drugs, and marketing status
Market growth drivers and challenges
The report segments the South America IBS-C Drugs market as:
South America IBS-C Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Brazil
Argentina
Venezuela
Colombia
Others
South America IBS-C Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
South America IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South America IBS-C Drugs Market: Players Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IBS-C DRUGS
1.1 Definition of IBS-C Drugs in This Report
1.2 Commercial Types of IBS-C Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Osmotic Laxatives
1.2.4 Stimulant Laxatives
1.2.5 Other
1.3 Downstream Application of IBS-C Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of IBS-C Drugs
1.5 Market Status and Trend of IBS-C Drugs 2013-2023
1.5.1 Europe IBS-C Drugs Market Status and Trend 2013-2023
1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of IBS-C Drugs in Europe 2013-2017
2.2 Consumption Market of IBS-C Drugs in Europe by Regions
2.2.1 Consumption Volume of IBS-C Drugs in Europe by Regions
2.2.2 Revenue of IBS-C Drugs in Europe by Regions
2.3 Market Analysis of IBS-C Drugs in Europe by Regions
2.3.1 Market Analysis of IBS-C Drugs in Germany 2013-2017
2.3.2 Market Analysis of IBS-C Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of IBS-C Drugs in France 2013-2017
2.3.4 Market Analysis of IBS-C Drugs in Italy 2013-2017
2.3.5 Market Analysis of IBS-C Drugs in Spain 2013-2017
2.3.6 Market Analysis of IBS-C Drugs in Benelux 2013-2017
2.3.7 Market Analysis of IBS-C Drugs in Russia 2013-2017
2.4 Market Development Forecast of IBS-C Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of IBS-C Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of IBS-C Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of IBS-C Drugs in Europe by Types
3.1.2 Revenue of IBS-C Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of IBS-C Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of IBS-C Drugs in Europe by Downstream Industry
4.2 Demand Volume of IBS-C Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of IBS-C Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of IBS-C Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of IBS-C Drugs by Downstream Industry in France
4.2.4 Demand Volume of IBS-C Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of IBS-C Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of IBS-C Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of IBS-C Drugs by Downstream Industry in Russia
4.3 Market Forecast of IBS-C Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 IBS-C Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of IBS-C Drugs in Europe by Major Players
6.2 Revenue of IBS-C Drugs in Europe by Major Players
6.3 Basic Information of IBS-C Drugs by Major Players
6.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Players
6.3.2 Employees and Revenue Level of IBS-C Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Catalent Pharmaceuticals Solutions
7.1.1 Company profile
7.1.2 Representative IBS-C Drugs Product
7.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions
7.2 Nestle
7.2.1 Company profile
7.2.2 Representative IBS-C Drugs Product
7.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
7.3 Abbott Laboratories
7.3.1 Company profile
7.3.2 Representative IBS-C Drugs Product
7.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.4 Synergy Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative IBS-C Drugs Product
7.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
7.5 Sucampo Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative IBS-C Drugs Product
7.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals
7.6 Novartis Pharma Ag
7.6.1 Company profile
7.6.2 Representative IBS-C Drugs Product
7.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
7.7 Astellas Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative IBS-C Drugs Product
7.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
7.8 Ardelyx, Inc
7.8.1 Company profile
7.8.2 Representative IBS-C Drugs Product
7.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
7.9 Synthetic Biologics, Inc
7.9.1 Company profile
7.9.2 Representative IBS-C Drugs Product
7.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc
7.10 Teva Pharmaceutical Industries
7.10.1 Company profile
7.10.2 Representative IBS-C Drugs Product
7.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
7.11 Bama-Geve, SLU
7.11.1 Company profile
7.11.2 Representative IBS-C Drugs Product
7.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
7.12 Ferring BV
7.12.1 Company profile
7.12.2 Representative IBS-C Drugs Product
7.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
7.13 Ironwood Pharmaceuticals, Inc
7.13.1 Company profile
7.13.2 Representative IBS-C Drugs Product
7.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc
7.14 Salix Pharmaceuticals Ltd
7.14.1 Company profile
7.14.2 Representative IBS-C Drugs Product
7.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
7.15 Norgine B.V
7.15.1 Company profile
7.15.2 Representative IBS-C Drugs Product
7.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
7.16 Prometheus Laboratories Inc
7.17 Actavis Nordic A/S
7.18 Albireo Pharma Inc
7.19 Yuhan Corp
7.20 Astrazeneca Plc
7.21 The Menarini Group
7.22 Ono Pharmaceutical Co., Ltd
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS
8.1 Industry Chain of IBS-C Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS
9.1 Cost Structure Analysis of IBS-C Drugs
9.2 Raw Materials Cost Analysis of IBS-C Drugs
9.3 Labor Cost Analysis of IBS-C Drugs
9.4 Manufacturing Expenses Analysis of IBS-C Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF IBS-C DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of IBS-C Drugs in This Report
1.2 Commercial Types of IBS-C Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Osmotic Laxatives
1.2.4 Stimulant Laxatives
1.2.5 Other
1.3 Downstream Application of IBS-C Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of IBS-C Drugs
1.5 Market Status and Trend of IBS-C Drugs 2013-2023
1.5.1 Europe IBS-C Drugs Market Status and Trend 2013-2023
1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of IBS-C Drugs in Europe 2013-2017
2.2 Consumption Market of IBS-C Drugs in Europe by Regions
2.2.1 Consumption Volume of IBS-C Drugs in Europe by Regions
2.2.2 Revenue of IBS-C Drugs in Europe by Regions
2.3 Market Analysis of IBS-C Drugs in Europe by Regions
2.3.1 Market Analysis of IBS-C Drugs in Germany 2013-2017
2.3.2 Market Analysis of IBS-C Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of IBS-C Drugs in France 2013-2017
2.3.4 Market Analysis of IBS-C Drugs in Italy 2013-2017
2.3.5 Market Analysis of IBS-C Drugs in Spain 2013-2017
2.3.6 Market Analysis of IBS-C Drugs in Benelux 2013-2017
2.3.7 Market Analysis of IBS-C Drugs in Russia 2013-2017
2.4 Market Development Forecast of IBS-C Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of IBS-C Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of IBS-C Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of IBS-C Drugs in Europe by Types
3.1.2 Revenue of IBS-C Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of IBS-C Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of IBS-C Drugs in Europe by Downstream Industry
4.2 Demand Volume of IBS-C Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of IBS-C Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of IBS-C Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of IBS-C Drugs by Downstream Industry in France
4.2.4 Demand Volume of IBS-C Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of IBS-C Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of IBS-C Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of IBS-C Drugs by Downstream Industry in Russia
4.3 Market Forecast of IBS-C Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 IBS-C Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of IBS-C Drugs in Europe by Major Players
6.2 Revenue of IBS-C Drugs in Europe by Major Players
6.3 Basic Information of IBS-C Drugs by Major Players
6.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Players
6.3.2 Employees and Revenue Level of IBS-C Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Catalent Pharmaceuticals Solutions
7.1.1 Company profile
7.1.2 Representative IBS-C Drugs Product
7.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions
7.2 Nestle
7.2.1 Company profile
7.2.2 Representative IBS-C Drugs Product
7.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
7.3 Abbott Laboratories
7.3.1 Company profile
7.3.2 Representative IBS-C Drugs Product
7.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.4 Synergy Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative IBS-C Drugs Product
7.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
7.5 Sucampo Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative IBS-C Drugs Product
7.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals
7.6 Novartis Pharma Ag
7.6.1 Company profile
7.6.2 Representative IBS-C Drugs Product
7.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
7.7 Astellas Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative IBS-C Drugs Product
7.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
7.8 Ardelyx, Inc
7.8.1 Company profile
7.8.2 Representative IBS-C Drugs Product
7.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
7.9 Synthetic Biologics, Inc
7.9.1 Company profile
7.9.2 Representative IBS-C Drugs Product
7.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc
7.10 Teva Pharmaceutical Industries
7.10.1 Company profile
7.10.2 Representative IBS-C Drugs Product
7.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
7.11 Bama-Geve, SLU
7.11.1 Company profile
7.11.2 Representative IBS-C Drugs Product
7.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
7.12 Ferring BV
7.12.1 Company profile
7.12.2 Representative IBS-C Drugs Product
7.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
7.13 Ironwood Pharmaceuticals, Inc
7.13.1 Company profile
7.13.2 Representative IBS-C Drugs Product
7.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc
7.14 Salix Pharmaceuticals Ltd
7.14.1 Company profile
7.14.2 Representative IBS-C Drugs Product
7.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
7.15 Norgine B.V
7.15.1 Company profile
7.15.2 Representative IBS-C Drugs Product
7.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
7.16 Prometheus Laboratories Inc
7.17 Actavis Nordic A/S
7.18 Albireo Pharma Inc
7.19 Yuhan Corp
7.20 Astrazeneca Plc
7.21 The Menarini Group
7.22 Ono Pharmaceutical Co., Ltd
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS
8.1 Industry Chain of IBS-C Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS
9.1 Cost Structure Analysis of IBS-C Drugs
9.2 Raw Materials Cost Analysis of IBS-C Drugs
9.3 Labor Cost Analysis of IBS-C Drugs
9.4 Manufacturing Expenses Analysis of IBS-C Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF IBS-C DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
